Atrial fibrillation (AF) care has advanced on three fronts — stroke prevention, rhythm control, and ablation technology — with a genuine technological leap in the last of these.
Stroke prevention
Direct oral anticoagulants remain the standard. The ARTESIA trial showed that in subclinical, device-detected AF, apixaban reduced stroke or systemic embolism compared with aspirin (hazard ratio 0.63), but at the cost of more major bleeding — so the net benefit is real but modest and individualized. The most active research frontier is factor XI inhibition, which aims to prevent clotting with less bleeding: the results have been mixed. The Phase 3 OCEANIC-AF trial of the oral factor XIa inhibitor asundexian was stopped early because it was inferior to apixaban for stroke prevention (though it did cause less bleeding), whereas the antibody abelacimab produced markedly less bleeding than rivaroxaban in AZALEA-TIMI 71 and continues in efficacy trials (LILAC-TIMI 76). The class is therefore promising for bleeding safety but not yet proven for efficacy. For patients unsuitable for long-term anticoagulation, left atrial appendage occlusion is an established alternative.
Rhythm control and ablation
The EAST-AFNET 4 trial showed that early rhythm-control therapy improves cardiovascular outcomes versus usual care in recently diagnosed AF, and EARLY-AF showed that first-line catheter cryoablation reduces progression to persistent AF compared with antiarrhythmic drugs. The biggest technological development is pulsed field ablation (PFA) — which uses cardioselective electroporation to ablate atrial tissue while largely sparing the esophagus and phrenic nerve. Multiple PFA systems gained FDA approval in 2024, and the ADVENT trial showed PFA non-inferior to conventional thermal ablation with comparable efficacy; large real-world registries have identified rare PFA-specific effects (transient hemolysis, coronary spasm) that inform technique. PFA has rapidly become a dominant ablation modality.
Further reading: ARTESIA apixaban in subclinical AF (Healey et al., NEJM 2024); EARLY-AF cryoablation (Andrade et al., NEJM 2023); EAST-AFNET 4 (Kirchhof et al., NEJM 2020); ADVENT pulsed field ablation (NEJM 2023); OCEANIC-AF and AZALEA-TIMI 71 factor XI inhibitor trials.